UK markets open in 7 hours 38 minutes

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7500-0.0400 (-2.23%)
At close: 04:00PM EDT
1.7100 -0.04 (-2.29%)
After hours: 07:07PM EDT

CytomX Therapeutics, Inc.

151 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 515 3185

Full-time employees120

Key executives

NameTitlePayExercisedYear born
Dr. Sean A. McCarthy DPHILChairman & CEO1.03MN/A1967
Dr. Marcia P. Belvin Ph.D.Senior VP & Chief Scientific Officer634.83kN/AN/A
Mr. Jeffrey Landau B.S., M.B.A.Senior VP, Head of Strategy & Chief Business Officer580.69kN/A1979
Mr. Christopher W. OgdenSenior VP of Finance & AccountingN/AN/A1984
Mr. Lloyd A. Rowland Jr., J.D.Senior VP, General Counsel, Chief Compliance Officer & Secretary608.72kN/A1957
Ms. Danielle Olander-MoghadassianSenior VP & Chief Human Resources OfficerN/AN/AN/A
Ms. Leslie RobbinsSenior Vice President of Intellectual PropertyN/AN/AN/A
Dr. Yu-Waye Chu M.D.Chief Medical OfficerN/AN/A1968
Ms. Dawn BensonSenior Vice President of Quality & Product ManufacturingN/AN/AN/A
Dr. Hoyoung Huh M.D., Ph.D.Special Advisor to Chief Executive Officer72.5kN/A1969
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Corporate governance

CytomX Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.